Given its central role in CCA pathogenesis, the PI3K/AKT/mTOR pathway has emerged as a promising therapeutic target, with several clinical trials investigating targeted agents at various levels of the signaling cascade. This evidence concerns the gene MTOR and cholangiocarcinoma.